United Nations 2030 Agenda for Sustainable Development and the Sustainable Development Goals

Patented Medicine Prices Review Board
UN Sustainable Development Goals (SDGs) 2022‒23 Planned initiatives Associated domestic targets or "ambitions" and/or global targets (United Nations Global Indicator Framework [GIF]; Canadian Indicator Framework [CIF]) 2022‒23 Results
SDG 10: Reduce inequality within and among countries
  • The Patented Medicine Price Regulation program is mandated to protect against excessive pricing of pharmaceuticals.
  • Although this mandate does not allow for price reviews to target priority equity groups, non-excessive prices for patented medicines will most benefit those directly affected by wealth inequality. Likewise, savings from any resultant price reductions can enable reinvestments in the health system.
  • The PMPRB's Internal Services is working towards the goals of the federal government's Procurement Strategy for Indigenous Businesses, which aims at 5.0% of the value of all federal contracts to be awarded to Indigenous suppliers.
  • The PMPRB has also developed a departmental Accessibility Plan in consultation with employees with disabilities to remove barriers in the workplace.
  • GIF Targets 10.2: By 2030, empower and promote the social, economic and political inclusion of all, irrespective of age, sex, disability, race, ethnicity, origin, religion or economic or other status; 10.3: Ensure equal opportunity and reduce inequalities of outcome, including by eliminating discriminatory laws, policies and practices and promoting appropriate legislation, policies and action in this regard; 10.4: Adopt policies, especially fiscal, wage and social protection policies, and progressively achieve greater equality.
  • CIF Ambition: Canadians live free of discrimination and inequalities are reduced
  • Amended Patented Medicine Regulations came into force on July 1, 2022, revising the list of countries used as comparators in the price review process. As the PMPRB uses this list to ensure that prices set in Canada are in line with peer countries, a broader basket of countries strengthens the accuracy and relevance of the price review process.
  • A total of 18.4% of the value of all PMPRB contracts were awarded to Indigenous suppliers in 2022-23.
  • Exceeding the goals of the federal government's Procurement Strategy for Indigenous Businesses allowed the PMPRB to diversify its contracted work, supports entrepreneurship in First Nations, Métis, and Inuit communities, and contributes to more equitable growth among Indigenous businesses.
  • The PMPRB's Accessibility Plan was published in December 2022.
SDG 12: Ensure sustainable consumption and production patterns The PMPRB’s Internal Services program has 2020–2023 FSDS targets supporting the Greening Government goal and the Policy on Green Procurement. These include relevant courses completed by decision-makers, the procurement of goods using recycled materials, and the sound and secure disposal of e-waste.
  • GIF Targets 12.5: By 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse; 12.7: Promote public procurement practices that are sustainable, in accordance with national policies and priorities; 12.8 By 2030, ensure that people everywhere have the relevant information and awareness for sustainable development and lifestyles in harmony with nature
  • CIF Ambition: Canadians consume in a sustainable manner
  • For results on these efforts, see the Reporting on Green Government supplementary information table.
  • Sustainable procurement practices can divert waste from landfills and ensure more accountability in the consumption cycle.
SDG 13: Take urgent action to combat climate change and its impacts
  • Health impacts and inequalities resulting from the effects of climate change will require flexibility in health system spending for payers in coming years.
  • The Patented Medicine Price Regulation program is an essential cog in the work underway to develop and maintain a sustainable healthcare system that will allow payers to be responsive to the changing needs of Canadians.
  • The Pharmaceutical Trends program contributes to this project by furnishing analytic reports that support informed policy development for initiatives such as the development of a national Pharmacare program, the establishment of a Canadian Drug Agency, and the development of a rare disease strategy.
  • GIF Targets 13.1: Strengthen resilience and adaptive capacity to climate-related hazards and natural disasters in all countries; 13.2: Integrate climate change measures into national policies, strategies and planning.
  • CIF Ambition: Canadians are well-equipped and resilient to face the effects of Climate change
  • The PMPRB continued to support health partners and other stakeholders through ad-hoc analytic work as well as the publication of several analytic reports in 2022-23.
  • The amended Patented Medicine Regulations brought into force on July 1, 2022, strengthen the PMPRB’s response to excessive pricing of patented medicines in Canada.

Back to top

Page details

Date modified: